Hudson Bay Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-74,800
| Closed | -$2.82M | – | 1271 |
|
|
2021
Q1 | $2.82M | Sell |
74,800
-375,200
| -83% | -$9.36M | 0.03% | 462 |
|
|
2020
Q4 | $7.66M | Buy |
450,000
+415,000
| +1,186% | +$5.2M | 0.08% | 154 |
|
|
2020
Q3 | $165K | Hold |
35,000
| – | – | ﹤0.01% | 497 |
|
|
2020
Q2 | $213K | Sell |
35,000
-105,000
| -75% | -$433K | ﹤0.01% | 435 |
|
|
2020
Q1 | $318K | Sell |
140,000
-220,000
| -61% | -$934K | 0.01% | 389 |
|
|
2019
Q4 | $1.65M | Sell |
360,000
-75,000
| -17% | -$297K | 0.04% | 299 |
|
|
2019
Q3 | $1.69M | Buy |
435,000
+15,000
| +4% | +$82.3K | 0.05% | 274 |
|
|
2019
Q2 | $2.53M | Buy |
420,000
+65,000
| +18% | +$621K | 0.06% | 249 |
|
|
2019
Q1 | $4.76M | Buy |
355,000
+5,000
| +1% | +$57K | 0.06% | 287 |
|
|
2018
Q4 | $3.25M | Buy |
350,000
+145,000
| +71% | +$1.73M | 0.04% | 399 |
|
|
2018
Q3 | $2.85M | Buy |
205,000
+55,000
| +37% | +$818K | 0.04% | 403 |
|
|
2018
Q2 | $2.37M | Buy |
150,000
+50,000
| +50% | +$873K | 0.03% | 465 |
|
|
2018
Q1 | $1.72M | Buy |
+100,000
| New | +$1.95M | 0.04% | 481 |
|
|
2017
Q3 | – | Sell |
-45,000
| Closed | -$1.35M | – | 578 |
|
|
2017
Q2 | $1.35M | Buy |
+45,000
| New | +$1.4M | 0.03% | 385 |
|
Hudson Bay Capital Management's FPRX Position: Q2 2021 in Review
Hudson Bay Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 74,800 shares — an estimated $2.82M sold.
Hudson Bay Capital Management first reported a position in FPRX in Q2 2017 and held it in 14 quarters. The position peaked at $7.66M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Hudson Bay Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Hudson Bay Capital Management sold 74,800 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.82M.
- Hudson Bay Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2017 and held it in 14 quarters.
- Hudson Bay Capital Management's Five Prime Therapeutics, Inc. position peaked at $7.66M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Hudson Bay Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.